Outset Medical (OM) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed Outset Medical (OM) over the past year, losing 35.9% versus a loss of 74.1%. Over five years, SERA leads with a -81.4% price change compared with -99.4% for OM. Sera Prognostics is the larger company by market cap ($79.7 million vs $76.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OM | SERA |
|---|---|---|
| Share price | $4.09 | $2.02 |
| Market cap | $76.88M | $79.69M |
| 1-day change | -2.85% | -2.42% |
| YTD return | +10.24% | -31.53% |
| 1-year return | -74.13% | -35.87% |
| 5-year return | -99.44% | -81.38% |
| EPS (TTM) | $-4.00 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.94 | $3.95 |
| 52-week low | $2.84 | $1.56 |
| Distance from 52-week high | -74.34% | -48.86% |
| Analyst consensus | buy | none |
| Avg. price target upside | +87.53% | +172.28% |
| Average volume | 158.75K | 28.38K |
| Shares outstanding | 18.80M | 38.48M |
| Employees | 310 | 71 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SERA has outperformed OM by 38.3 percentage points over the past year.
About Outset Medical
OM stock →Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Healthcare · Medical Devices · 310 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Healthcare · Medical Devices · 71 employees
OM vs SERA FAQ
Which is bigger, Outset Medical or Sera Prognostics?
Sera Prognostics (SERA) is larger, with a market capitalization of $79.69M compared with $76.88M for Outset Medical (OM).
Which stock has performed better over the past year, OM or SERA?
SERA returned -35.87% over the past 12 months, compared with -74.13% for OM (price return, excluding dividends). Past performance does not predict future results.
Are Outset Medical and Sera Prognostics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.